Mainspring is pleased to report that Syncona, a leading healthcare company focused on investing in and building global leaders in life science, released its full-year results on 6th July 2017, confirming a 12.5% total return and enlarged net assets of £895.2m. Its largest life sciences holding, Blue Earth, had gained approval for Axumin, its PET imaging diagnostic agent for prostate cancer in May 2017.
Mainspring provides Syncona with a broad and customised middle office solution with the core objectives of reducing its internal administrative efforts, improving public and performance reporting and helping it to meet regulatory and compliance requirements.
Stephen Geddes, CEO of Mainspring, commented “It is such excellent news to see tangible life sciences progress coupled with investment growth. Our relationship started in June 2014 with BACIT (Battle Against Cancer Investment Trust) and this continued with the acquisition of the Wellcome Trust’s investment subsidiary Syncona Partners in December 2016. We very much look forward to continuing to support Syncona, assisting with the weight of internal administration, reporting & compliance and thereby giving Syncona the space to focus on life sciences development and investment growth.”